Cencora, Inc. (LON:0HF3)
371.59
+10.38 (2.87%)
Feb 12, 2026, 4:54 PM GMT
Cencora Revenue
Cencora had revenue of $85.93B USD in the quarter ending December 31, 2025, with 5.45% growth. This brings the company's revenue in the last twelve months to $325.78B, up 7.45% year-over-year. In the fiscal year ending September 30, 2025, Cencora had annual revenue of $321.33B with 9.31% growth.
Revenue (ttm)
$325.78B
Revenue Growth
+7.45%
P/S Ratio
0.22
Revenue / Employee
$6.39M
Employees
51,000
Market Cap
52.14B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 321.33B | 27.37B | 9.31% |
| Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
| Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
| Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
| Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
| Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
| Sep 30, 2019 | 179.59B | 11.65B | 6.94% |
| Sep 30, 2018 | 167.94B | 14.80B | 9.66% |
| Sep 30, 2017 | 153.14B | 6.29B | 4.29% |
| Sep 30, 2016 | 146.85B | 10.89B | 8.01% |
| Sep 30, 2015 | 135.96B | 16.39B | 13.71% |
| Sep 30, 2014 | 119.57B | 31.61B | 35.94% |
| Sep 30, 2013 | 87.96B | 9.88B | 12.65% |
| Sep 30, 2012 | 78.08B | -614.85M | -0.78% |
| Sep 30, 2011 | 78.70B | 919.20M | 1.18% |
| Sep 30, 2010 | 77.78B | 6.02B | 8.38% |
| Sep 30, 2009 | 71.76B | 1.57B | 2.24% |
| Sep 30, 2008 | 70.19B | 8.92B | 14.56% |
| Sep 30, 2007 | 61.27B | 454.37M | 0.75% |
| Sep 30, 2006 | 60.81B | 10.80B | 21.59% |
| Sep 30, 2005 | 50.01B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| CVS Group | 673.20M |
| Genus | 672.80M |
Cencora News
- 1 day ago - Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056 - Business Wire
- 8 days ago - Cencora, Inc. (COR) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Cencora beats quarterly profit estimates on strong demand for specialty medicines - Reuters
- 8 days ago - Cencora Reports Fiscal 2026 First Quarter Results - Business Wire
- 21 days ago - Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products - Business Wire
- 21 days ago - Cencora Elects Ellen Cooper to Its Board of Directors - Business Wire
- 22 days ago - Cencora: High-Growth Specialty Services Firm Disguised As A Distributor - Seeking Alpha
- 4 weeks ago - Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha